Clinical Trials

52 enrolled

Breast Neoplasms

NCT04877821 2026-04-02

NeoSACT

Phase 2 Completed

29 enrolled

Triple Negative Breast Neoplasms

NCT07396454 2026-02-09

Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib

39 enrolled

HER2-Negative Breast Cancer

NCT07330544 2026-01-09

A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

118 enrolled

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT07139470 2025-08-24

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

59 enrolled

Triple Negative Breast Neoplasms

NCT06874933 2025-08-12

Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)

35 enrolled

Breast Neoplasms

NCT06992336 2025-05-28

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

411 enrolled

Breast Neoplasms

NCT06678230 2024-11-07

Clinical Trial of Eribulin in Combination with Anrotinib for HER-2 Negative Locally Advanced or Metastatic Breast Cancer

Phase NA Not yet recruiting

Breast Neoplasms

NCT06605690 2024-09-20

An Exploratory Clinical Study of Dalpiciclib an&Amp;#39;d Letrozole Combined With Anlotinib Neoadjuvant Therapy in Stage II-III Postmenopausal HR+/HER2- Early Breast Cancer

30 enrolled

Breast Neoplasms

NCT06331169 2024-08-30

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Phase 1 Recruiting

42 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Breast Neoplasms

NCT04914390 2024-01-22

NeoATCT

32 enrolled

Triple Negative Breast Neoplasms

NCT05296577 2023-09-25

Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast Cancer

134 enrolled

Breast Neoplasms

NCT06015126 2023-08-29

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Phase NA Unknown

60 enrolled

Breast Neoplasms

NCT05206656 2022-11-23

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Phase 2 Completed

80 enrolled

Breast Neoplasms

NCT05558722 2022-09-28

ACNTBC

30 enrolled

Breast Neoplasms

NCT05089643 2022-01-10

Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer

35 enrolled

Triple Negative Breast Neoplasms

NCT05075512 2021-10-12

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Breast Neoplasm Female

NCT04975451 2021-07-27

ADCb (Anlotinib/Docetaxel/Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer

30 enrolled

Breast Neoplasms

NCT04452370 2021-07-21

Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT04936295 2021-06-23

Fulvestrant Plus Anlotinib in HR(+)/HER2(-) Metastatic Breast Cancer With FGFR Mutation

61 enrolled

Breast Neoplasms

NCT04624711 2021-05-21

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

HER2-negative Breast Cancer

NCT04764084 2021-02-21

Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors

Phase 1 Unknown

52 enrolled

BreastGastrointestinal

Breast Neoplasms, Pancreatic Neoplasms, Cholangiocarcinoma

NCT04002284 2020-07-29

Anlotinib in Metastatic HER2 Negative Breast Cancer

Phase 2 Completed

26 enrolled

Breast Neoplasms

NCT04405505 2020-05-28

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Phase 3 Unknown

332 enrolled